Research progress of antiplatelet therapy for high-risk non-disabling ischemic cerebrovascular events
10.3969/j.issn.1004-1648.2024.05.015
- VernacularTitle:高危非致残缺血性脑血管事件抗血小板治疗的研究进展
- Author:
Mingli WANG
1
;
Rui CHEN
;
Xiaoli LIU
Author Information
1. 116011 大连医科大学附属第一医院神经内科
- Keywords:
high-risk non-disabling ischemic cerebrovascular events;
antiplatelet therapy;
clopidogrel;
ticagrelor
- From:
Journal of Clinical Neurology
2024;37(5):379-383
- CountryChina
- Language:Chinese
-
Abstract:
High-risk non-disabling ischemic cerebrovascular events have a high risk of early stroke recurrence.Antiplatelet therapy is the cornerstone of the treatment.Short-term dual antiplatelet therapy can reduce the risk of stroke recurrence at 90 d,but there are still some patients with poor response to antiplatelet therapy,and antiplatelet drug resistance is one of the important reasons leading to reduced platelet efficacy.In patients with clopidogrel resistance,dual antiplatelet therapy with ticagrelor replacement is a good option.At present,the effect of dual antiplatelet therapy is still not ideal,and the combination of intensive lipid-lowering therapy and anti-inflammatory therapy may have more benefits.
